BRIEF-Alnylam To Invest $250 Million To Add Enzymatic Ligation Platform

Reuters12-17 21:08

Dec 17 (Reuters) - Alnylam Pharmaceuticals Inc ALNY.O:

ALNYLAM TO INVEST $250 MILLION TO ADD ENZYMATIC LIGATION PLATFORM TO U.S. MANUFACTURING FACILITY TO MEET GROWING GLOBAL DEMAND FOR RNAI THERAPEUTICS
ALNYLAM PHARMACEUTICALS INC - NEW CAPABILITIES OPERATIONAL BY LATE 2027

Source text: ID:nBw3ds0Nma

Further company coverage: ALNY.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592990467?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 21:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592990467","market":"nz","top_or_hot":-1,"title":"BRIEF-Alnylam To Invest $250 Million To Add Enzymatic Ligation Platform","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Alnylam To Invest $250 Million To Add Enzymatic Ligation Platform </title></head><body><p><span>Dec 17 (Reuters)</span><span> - </span>Alnylam Pharmaceuticals Inc <span>ALNY.O</span>:</p><ul><li><p>ALNYLAM TO INVEST $250 MILLION TO ADD ENZYMATIC LIGATION PLATFORM TO U.S. MANUFACTURING FACILITY TO MEET GROWING GLOBAL DEMAND FOR RNAI THERAPEUTICS</p></li><li><p>ALNYLAM PHARMACEUTICALS INC - NEW CAPABILITIES OPERATIONAL BY LATE 2027</p></li></ul><p>Source text: <span>ID:nBw3ds0Nma</span></p><p>Further company coverage: <span>ALNY.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Alnylam To Invest $250 Million To Add Enzymatic Ligation Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Alnylam To Invest $250 Million To Add Enzymatic Ligation Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-17 21:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Alnylam To Invest $250 Million To Add Enzymatic Ligation Platform </title></head><body><p><span>Dec 17 (Reuters)</span><span> - </span>Alnylam Pharmaceuticals Inc <span>ALNY.O</span>:</p><ul><li><p>ALNYLAM TO INVEST $250 MILLION TO ADD ENZYMATIC LIGATION PLATFORM TO U.S. MANUFACTURING FACILITY TO MEET GROWING GLOBAL DEMAND FOR RNAI THERAPEUTICS</p></li><li><p>ALNYLAM PHARMACEUTICALS INC - NEW CAPABILITIES OPERATIONAL BY LATE 2027</p></li></ul><p>Source text: <span>ID:nBw3ds0Nma</span></p><p>Further company coverage: <span>ALNY.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA9XHXBG:1","article_id":"2592990467","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592990467","pubTimestamp":1765976896,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Alnylam To Invest $250 Million To Add Enzymatic Ligation Platform Dec 17 (Reuters) - Alnylam Pharmaceuticals Inc ALNY.O:ALNYLAM TO INVEST $250 MILLION TO ADD ENZYMATIC LIGATION PLATFORM TO U.S. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4585":"ETF&股票定投概念","LU0882574055.USD":"富达全球健康医疗A ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","ALNY":"阿尔尼拉姆制药公司","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4588":"碎股","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4548":"巴美列捷福持仓"},"translate_title":"简介-Alnylam将投资2.5亿美元添加酶连接平台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALNY":0.9},"content_text":"BRIEF-Alnylam To Invest $250 Million To Add Enzymatic Ligation Platform Dec 17 (Reuters) - Alnylam Pharmaceuticals Inc ALNY.O:ALNYLAM TO INVEST $250 MILLION TO ADD ENZYMATIC LIGATION PLATFORM TO U.S. MANUFACTURING FACILITY TO MEET GROWING GLOBAL DEMAND FOR RNAI THERAPEUTICSALNYLAM PHARMACEUTICALS INC - NEW CAPABILITIES OPERATIONAL BY LATE 2027Source text: ID:nBw3ds0NmaFurther company coverage: ALNY.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592990467","isCrawlerRequest":true}